Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

23.86
-0.1100-0.46%
Volume:361.85K
Turnover:8.64M
Market Cap:2.98B
PE:110.76
High:24.11
Open:23.79
Low:23.75
Close:23.97
52wk High:31.77
52wk Low:15.13
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.32
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:13.53
PE(LYR):-188.08

Loading ...

Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4

Reuters
·
May 09

Arcutis grants 269,000 RSUs, 70,000 stock options to new hires under inducement plan

Reuters
·
May 09

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 09

Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley

TIPRANKS
·
May 08

Stock Track | Arcutis Biotherapeutics Plunges 5.23% in Pre-market Following Q1 Earnings Miss and Insider Selling

Stock Track
·
May 07

Arcutis Biotherapeutics Price Target Maintained With a $36.00/Share by Needham

Dow Jones
·
May 07

Analysts Conflicted on These Healthcare Names: Quanterix (QTRX) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
May 07

Stock Track | Arcutis Biotherapeutics Plunges 6.91% After Q1 Earnings Miss Estimates

Stock Track
·
May 07

Arcutis Chief Legal Officer Masaru Matsuda disposes 8,256 shares worth $192,893

Reuters
·
May 07

Arcutis Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Arcutis Q1 FY26 net loss narrows to USD 11.3 million; revenue rises 65% to USD 105.4 million

Reuters
·
May 07

Arcutis Biotherapeutics Q1 EPS USD -0.09

THOMSON REUTERS
·
May 07

Arcutis Biotherapeutics Q1 Product Revenue USD 105.398 Million

THOMSON REUTERS
·
May 07

Arcutis Biotherapeutics Inc - Sees FY2026 Net Product Revenue $480 Mln-$495 Mln

THOMSON REUTERS
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Arcutis director Howard Welgus sells 7,144 shares for $164,203.54

Reuters
·
May 06

Earning Preview: Arcutis Biotherapeutics Inc. this quarter’s revenue is expected to increase by 62.67%, and institutional views are bullish

Earnings Agent
·
Apr 30

Arcutis submits FDA sNDA for Zoryve cream use in infants with atopic dermatitis

Reuters
·
Apr 27

Arcutis Submits Supplemental New Drug Application to the FDA for Zoryve® (Roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

THOMSON REUTERS
·
Apr 27

A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Pediatric Guidelines For ZORYVE

Simply Wall St.
·
Apr 25